Study of Memantine to Treat Huntington's Disease

Completed · Phase 4 · Has a placebo group

Conditions studied: Huntington's Disease

In brief

To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).

Key facts

Study ID

NCT00652457

Run by

Jody Corey-Bloom, MD, PhD

People needed

50

Starts

2004-11-23

Expected to finish

2009-10-28

Last updated by the study team

2021-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women aged 18 or older.
• Diagnosis of HD with current complaints of memory or concentration difficulties.
• Dementia Rating Scale score of <129, to ensure that patients have sufficient cognitive impairment.
• Adequate visual and auditory acuity to allow neuropsychological testing.
• Good general health with no additional diseases expected to interfere with the study.
• Patient is not institutionalized.
• Sufficient English skills to complete all testing without assistance of an English language interpreter.
• Availability of a responsible caregiver who agrees to supervise administration of study drug, monitor the patient's compliance and adverse events, and accompany the patient to all clinic visits.

You may not qualify if…

• 1. Any significant neurologic disease other than HD.
• Severe psychotic features or other severe psychiatric problems within the last three months which could lead to difficulty complying with the protocol.
• History of alcohol or substance abuse within the past two years (DSM IV criteria).
• Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
• History of MI in the past year or head trauma with loss of consciousness greater than 20 minutes.
• Insulin-requiring diabetes.
• Use of any FDA approved cognitive enhancing prescription medications or investigational drugs within 30 days.
• Use of ginkgo biloba or DHEA within four weeks prior to baseline.
• Use of narcotic analgesics within 4 weeks prior to baseline.
• Patients who, in the investigator's opinion, would not comply with study procedures.

Where it is running

• University of California, San Diego — La Jolla, California, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.